On February 17, 2026, Sessa Capital disclosed a major buy of Sotera Health (NASDAQ:SHC), adding 10,630,381 shares in an estimated $175.80 million trade based on quarterly average pricing. What happened According to a filing with the Securities and Exchange Commission dated February 17, 2026, Sessa Capital purchased 10,630,381 additional shares of Sotera Health in the fourth quarter. The estimated transaction value is $175.80 million, calculated using the average closing price for the quarter. The fund’s ...

Company Overview - Sotera Health is a leading provider of sterilization and laboratory testing solutions, serving critical sectors such as healthcare and pharmaceuticals [6] - The company operates with a diversified portfolio of services to meet regulatory and safety requirements for a global client base, including medical device manufacturers and pharmaceutical companies [9] Financial Performance - Sotera Health reported a total revenue of $1.16 billion for the trailing twelve months (TTM) [4] - The net income for the same period was $77.95 million, with a significant year-over-year increase [11] - The company achieved its 20th consecutive year of revenue growth, with net revenues rising nearly 6% in 2025 and adjusted EBITDA climbing 8% to $594 million [11] - Management has guided for a revenue increase of 5% to 6.5% in 2026, alongside adjusted EBITDA growth of 5.5% to 7.0% [11] Stock Performance - As of February 17, 2026, shares of Sotera Health were priced at $17.09, reflecting a nearly 30% increase over the past year, outperforming the S&P 500 by 14.86 percentage points [8] - The reduction in Ananym Capital Management's stake in Sotera Health lowered its position to 8.65% of the fund's 13F reportable assets under management (AUM) as of December 31, 2025 [8] Market Position - Sotera Health operates mission-critical sterilization and testing infrastructure that is essential for medical device and pharmaceutical companies, making it a non-speculative investment [12] - The company has improved cash flow, reduced leverage to 3.2 times adjusted EBITDA, and strengthened liquidity [12] Investment Perspective - The modest reduction in Ananym Capital Management's position is viewed as risk management following a strong performance rather than a loss of confidence in Sotera Health's business model [10] - Long-term investors are encouraged to focus on the company's consistent revenue growth over two decades in a sector where reliability is crucial [13]